Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of appx. SEK 82.5 million (the “Rights Issue”), for which the subscription period ended on 25 March 2026. The Rights Issue has been subscribed to 63.3 percent with and without the support of subscription rights, of which appx. 62.7 percent was subscribed for with the support of subscription rights and appx. 0.6 percent was subscribed for without the support of subscription rights. Underwriting commitments of 75,606,289 shares, corresponding to 36.7 percent of the Rights Issue, will thus be utilized. The Rights Issue was thus subscribed to 100 percent. Through the Rights Issue, the Company will receive appx. SEK 82.5 million before deduction of transaction costs and before set-off of loans.
About the Rights Issue
Those who on the record date 9 March 2026 were registered shareholders in the share register maintained by Euroclear Sweden AB received one (1) subscription right for each existing share. Three (3) subscription rights entitled the holder to subscribe for seven (7) new shares. The subscription price was SEK 0.40 per share. In addition, the opportunity was offered to register for subscription of shares without the support of subscription rights. The Rights Issue was fully covered by subscription commitments and guarantee commitments.
Final outcome
In the Rights Issue, 129,384,682 shares were subscribed for with subscription rights, corresponding to appx. 62.7 percent of the Rights Issue. In addition, 1,205,271 shares were subscribed for without the support of subscription rights, corresponding to appx. 0.6 percent of the Rights Issue. Together, subscription with and without the support of subscription rights corresponds to 63.3 percent of the Rights Issue.
Due to the subscription level, the underwriting commitment from Flerie Invest AB (“Flerie“) will be utilized for 34,969,679 shares, corresponding to appx. 17 percent of the Rights Issue. In addition, the bottom guarantees will be utilized for 40,636,610 shares, corresponding to the remaining appx. 19.7 percent of the Rights Issue.
Payment for the shares subscribed for by Flerie in the Rights Issue will be made by set-off of receivables that Flerie has against the Company. In total, appx. SEK 48.8 million, corresponding to appx. 59.2 percent of the Rights Issue, will be set off, whereby Flerie’s outstanding loans to the Company are repaid in full. The remaining portion of the shares allotted to Flerie will be paid in cash, appx. SEK 1.1 million.
Through the Rights Issue, Nanologica will receive appx. SEK 82.5 million before deduction of transaction costs and before set-off of loans. The costs related to the Rights Issue and the directed issues resolved by the board of directors on 30 January 2026 are estimated to amount to a total of appx. SEK 6.5 million.
Notification of allotment
Allotment of shares has been made in accordance with the allotment principles set out in the information document published on 6 March 2026. Subscribed and allotted shares shall be paid in cash in accordance with the instructions on the settlement note. Investors who have subscribed for shares through a nominee will receive notification of allotment in accordance with the respective nominee’s procedures. Only those who have been assigned shares will be notified.
Trading in BTA
Trading in BTA (paid subscribed share) is currently conducted on Nasdaq Stockholm and will cease after the Rights Issue has been registered with the Swedish Companies Registration Office. BTA will then be converted into shares. The last day of trading in BTA is estimated to be 10 April 2026.
Number of shares, share capital and dilution
Through the Rights Issue, the number of shares in Nanologica will increase by 206,196,246 shares and the share capital will increase by SEK 10,516,008.55. Registration of the directed issue of 12,750,000 shares, resolved by the board of directors on 30 January 2026 and approved at the extraordinary general meeting on 4 March 2026, is ongoing. Following the directed issue and the Rights Issue, the total number of shares in the Company will amount to 328,769,846 shares and the share capital will amount to SEK 16,767,262.146.
Advisors
Nanologica has engaged Redeye AB and Navia Corporate Finance AB as Joint Bookrunner and Bergs Securities AB as Joint Bookrunner and issuing agent, and Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue.